antipsychotic medications

DRUG2 trials

Sponsors

Janssen-Cilag, S.A., Central South University

Conditions

Metabolic SyndromeSchizoaffective DisorderSchizophreniaSchizophreniform Disorder

Unknown Phase

PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders

CompletedNCT00399334

Janssen-Cilag, S.A.Schizoaffective Disorder, Schizophrenia, Schizophreniform Disorder

Start: 2005-06-30End: 2005-12-31Updated: 2011-05-19

Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients

CompletedNCT03451734

Central South UniversityMetabolic Syndrome, Schizophrenia

Start: 2018-01-23End: 2021-06-30Updated: 2021-08-12

Related Papers

Association between baseline cognition and clinical response in first-episode schizophrenia

BMC Psychiatry2026-08-05

Relationship between cognitive impairments and psychopathological symptoms in female schizophrenia subsequent to 8 weeks treatment with antipsychotic drugs

BMC Psychiatry2025-03-071 citations

Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial

Lipids in Health and Disease2024-07-242 citations

The association of SOD and HsCRP with the efficacy of sulforaphane in schizophrenia patients with residual negative symptoms.

2023-09-209 citations

Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.

2023-07-194 citations

Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial

Frontiers in Psychiatry2021-02-2527 citations

The Association Between Cognitive Deficits and Clinical Characteristic in First-Episode Drug Naïve Patients With Schizophrenia

Frontiers in Psychiatry2021-02-2515 citations

The Association Between Metabolic Disturbance and Cognitive Impairments in Early-Stage Schizophrenia

Frontiers in Human Neuroscience2021-02-2212 citations

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients

Frontiers in Pharmacology2020-05-2238 citations